News

Both the willingness-to-pay threshold and patient body weight need to be considered when deciding between nivolumab and pembrolizumab for treating platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma.

Study findings show higher insurer spending for a surgical episode among patients with private insurance undergoing treatment at National Cancer Institute centers than in community hospitals, without differences in care utilization.

Regionalization of gastric cancer care in a US integrated healthcare system increased care specialization and standardization, improving clinical outcomes for patients.

High intensity dosing of carfilzomib as a single agent or in combination with dexamethasone may improve outcomes among patients with MM.

Study identifies hospital characteristics that may require special consideration as alternative payment models expand in oncology care.

The use of presurgical testing guidelines for patients with endometrial pathology undergoing hysterectomy in the ambulatory setting is safe and cost-effective.

Study findings suggest that many patients with head and neck cancers received imaging beyond what is recommended by the NCCN guidelines, and the cost burden of imaging asymptomatic patients needs to be considered.

Study findings suggest that sex, race/ethnicity, and insurance status are associated with significant disparities in the receipt of guideline-based treatment for kidney cancer.

Study findings suggest survival among patients with ERBB2-positive metastatic breast cancer receiving pertuzumab and trastuzumab emtansine (T-DM1) in the real-world setting appears inferior to results from pivotal clinical trials.

Findings from a recent study indicate that intervention may be needed to optimize health care delivery and end-of-life care in patients with hematologic malignancies receiving CAR-T therapy.